Francisco Beça

envie a um amigo share this

Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials

Francisco Beça: Department of Pathology and Cancer Research Institute, Beth Israel Deaconess Cancer Center, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials

Numa edição especial intitulada «Translating the Cancer Genome — Implications for Diagnosis and Treatment», da conceituada revista PLoS Medicine, o médico e investigador português Francisco Beça, juntamente com Andrew Beck, discutem um artigo da equipa liderada por Charles Swanton e partilham as suas perspetivas sobre o estado atual da Precision Medicine com especial foco no cancro da mama.

LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer

Authors and Affiliations:

Whitney S. Henry1,*, David G. Hendrickson2,3,*, Francisco Beca1,3, Benjamin Glass1,3, Marianne Lindahl-Allen4, Lizhi He4, Zhe Ji4, Kevin Struhl4, Andrew H. Beck1,3, John L. Rinn2,3 and Alex Toker1

1 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

O papel do lncRNA LINC00520 no desenvolvimento de cancro da mama

Num esforço colaborativo de investigadores do Centro de Cancro do Beth-Israel Deaconess Medical Center e Harvard Medical School, que contou com a participação do medico investigador português Francisco Beça, actualmente faculty da Harvard Medical School, foram descobertos vários long non-coding RNA (lncRNAs) potencialmente implicados no desenvolvimento de cancro da mama.

New biomarkers identify luminal aggressive type of breast carcinomas

Authors and Affiliations:

Francisco Beça - IPATIMUP – Institute of Molecular Pathology and Immunology of the University of Porto, Rua Dr, Roberto Frias, s/n, 4200-465 Porto, Porto, Portugal; Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brooklin Ave., Boston 02215-5450, MA, USA

Miguel Pereira - Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston 02114, MA, USA

Novos biomarcadores identificam carcinomas de mama de tipo luminal agressivos

Recentemente, deleções no locus contendo o gene PPP2R2A, que codifica a proteína B55α, uma subunidade regulatória da PP2A (Protein Phosphatase 2), foram associadas a um subgrupo de cancro da mama, ER (receptores de estrogénio) positivos muito agressivos. No mesmo trabalho, este subgrupo de carcinomas, denominado Integrative Custer 2, caracterizava-se ainda por amplificações de uma da região 11q13, que entre outros, contém o gene CCND1 que codifica a Ciclina D1. 

p-mTOR expression is associated with prognosis in luminal breast carcinoma

Francisco Beça1,2,3, Rosário André4,5, Duarte Saraiva Martins6, Tiago Bilhim7, Diana Martins2, Fernando Schmitt2,8,9

1 - Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, USA

2 - IPATIMUP—Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal

3 - Faculty of Medicine, Department of Pathology and Oncology, University of Porto, Porto, Portugal

p-mTOR expression is associated with prognosis in luminal breast carcinoma

Francisco Beça1,2,3, Rosário André4,5, Duarte Saraiva Martins6, Tiago Bilhim7, Diana Martins2, Fernando Schmitt2,8,9

1 - Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, USA

2 - IPATIMUP—Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal

3 - Faculty of Medicine, Department of Pathology and Oncology, University of Porto, Porto, Portugal